🔗 Share this article

While America undertakes sweeping revisions to its vaccination recommendations, one figure has surfaced somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations in the global health crisis and has zeroed in on possible fatalities after COVID-19 immunization in her recent tenure at the FDA.

Proposed Overhauls to Pediatric Vaccine Program

Health officials planned to reveal major changes to the childhood vaccination calendar recently, bringing the US with Denmark’s national calendar, it is understood – a major change that would place the US at odds with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood shot schedules in the US so as to align more similar to the Danish model, a nation with nationalized medicine and a citizenry about the size of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccines – usually the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the CDER, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She lacks background in industry regulation.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who led CBER have had.”

This division has an vast workload at the FDA, Woodcock stated.

“The public just pays attention on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and all of those have to be looked after,” Dr. Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major leadership element to the position, which supervises more than 5,000 employees. “It’s a enormous leadership role, if you do it right,” Woodcock concluded.

Response and Controversial Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this selection signifies greater collaboration among FDA leaders on vaccines, a press secretary stated that the “inquiries stem from flawed premises”.

“This background matches the responsibilities of her role,” the spokesperson said, noting the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a controversial rapid drug-approval program that allegedly worried her predecessors. “By what process are these therapies being chosen for this voucher program? Who is making the decisions?” Dr. Howard said. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards laxer rules of most medications, aside from vaccines.”

Established Past Work on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, past, Howard have noted. She published a study using non-validated public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming government included altering guidelines for recently developed shots and ending “unnecessary” vaccines, she remarked following the vote on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of barring young men from getting COVID-19 vaccines.

“She is an all-around true believer who starts off with her preconceived notions and tailors the evidence to accommodate the science in a extremely disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|